- Details
- Description
-
Packaging Size30T/bottle
-
Strength2mg
-
CompositonTrametinib
-
TreatmentBRAF V600E Mutation-Positive Solid Tumors,Melanoma,Non-Small Cell Lung Cancer,Locally Advanced or Metastatic Thyroid Cancer,
-
FormTablet
-
BrandTRAMEDX
-
Quantity Unit2mg*30T/bottle
-
ManufacturerBIGBEAR Pharma,Laos PDR
Trametinib is a kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer.
Melanoma
Also see Administration
Mutations must be detected by an FDA-approved test
BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma
- Indicated, as a single agent or in combination with dabrafenib
- 2 mg PO qDay
- May also be used in combination with dabrafenib 150 mg PO BID
- Continue until disease recurrence or unacceptable toxicity
Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma
- Indicated, in combination with dabrafenib, for mutation-positive and involvement of lymph node(s), following complete resection
- 2 mg PO qDay plus dabrafenib 150 mg PO BID
- Continue until disease recurrence or unacceptable toxicity for up to 1 year
Non-Small Cell Lung Cancer
Indicated in combination with dabrafenib for unresectable or metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
2 mg PO qDay plus dabrafenib 150 mg PO BID
Continue treatment until disease progression or unacceptable toxicity
Thyroid Cancer
Indicated, in combination with dabrafenib, for locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation in adults with no satisfactory locoregional treatment options
2 mg PO qDay plus dabrafenib 150 mg PO BID
Continue treatment until disease progression or unacceptable toxicity
BRAF V600E Mutation-Positive Solid Tumors
Indicated in combination with dabrafenib for unresectable or metastatic solid tumors with BRAF V600E mutation in patients who have progressed following prior treatment and have no satisfactory alternative treatment options
2 mg PO qDay plus dabrafenib 150 mg PO BID
Continue treatment until disease progression or unacceptable toxicity
